The estimated Net Worth of Mark Pulido is at least $10.6 Million dollars as of 18 June 2021. Mr. Pulido owns over 9,165 units of Innovator ETFs Trust stock worth over $7,682,857 and over the last 20 years he sold INOV stock worth over $2,639,000. In addition, he makes $250,000 as Non-Independent Director at Innovator ETFs Trust.
Sign up
Mr. Pulido INOV stock SEC Form 4 insiders trading
Mark has made over 11 trades of the Innovator ETFs Trust stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 9,165 units of INOV stock worth $266,793 on 18 June 2021.
The largest trade he's ever made was selling 100,000 units of Innovator ETFs Trust stock on 5 February 2021 worth over $2,639,000. On average, Mark trades about 7,614 units every 131 days since 2004. As of 18 June 2021 he still owns at least 263,925 units of Innovator ETFs Trust stock.
You can see the complete history of Mr. Pulido stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Pulido biography
Mark A. Pulido serves as Non-Independent Director of the Company since April 2018. Prior to joining Inovalon's Board, Mr. Pulido served on the Board, from 2011, as Chairman of the Board, from 2014, and as CEO, from 2015, of ABILITY Network, a national leader in cloud-based solutions for the healthcare provider marketplace until Inovalon's acquisition of ABILITY Network in April 2018. Prior to his role at ABILITY, Mr. Pulido focused on private equity and investing initiatives as an industry executive at Freeman Spogli & Company from 2004 to 2015. From 2000 to 2002, he served as the Chairman of BenefitPoint, Inc., a venture capital-backed employee benefits technology company, where he also served as its President and Chief Executive Officer. Prior to that, Mr. Pulido served as President and CEO of McKesson Corporation, a Fortune 15 healthcare services and information technology company, from 1996 to 1999; President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, USA (formerly Sandoz), a research-based pharmaceutical manufacturer, from 1994 to 1996; and Chairman, President and CEO of Red Line Healthcare Corporation, a specialty long-term care distribution and medical billing company, from 1990 to 1994. Mr. Pulido also previously served as Chairman of the Board of Directors of Quidel Corporation, a manufacturer of diagnostic testing solutions and as a board member of several healthcare and technology companies, including Sunrise Medical Inc., a medical equipment manufacturer; Smile Brands Group, a dental practice management company; Charles Schwab Corporation, a financial services company; and Imation Corporation, a technology company. Mr. Pulido holds a Bachelor of Science degree in Pharmacy from the University of Arizona, College of Pharmacy, and a Masters of Science degree in Pharmacy Administration from the University of Minnesota.
What is the salary of Mark Pulido?
As the Non-Independent Director of Innovator ETFs Trust, the total compensation of Mark Pulido at Innovator ETFs Trust is $250,000. There are 5 executives at Innovator ETFs Trust getting paid more, with Peter De Bock having the highest compensation of $2,866,730.
How old is Mark Pulido?
Mark Pulido is 67, he's been the Non-Independent Director of Innovator ETFs Trust since 2018. There are 2 older and 9 younger executives at Innovator ETFs Trust. The oldest executive at Innovator ETFs Trust is Denise Fletcher, 71, who is the Independent Director.
What's Mark Pulido's mailing address?
Mark's mailing address filed with the SEC is 4321, Collington Road, Essington, Bowie, Prince George's County, Maryland, 20716, United States.
Insiders trading at Innovator ETFs Trust
Over the last 10 years, insiders at Innovator ETFs Trust have traded over $17,222,256 worth of Innovator ETFs Trust stock and bought 1,096,675 units worth $14,934,745 . The most active insiders traders include Keith R Dunleavy, Christopher E Greiner, and William D Green. On average, Innovator ETFs Trust executives and independent directors trade stock every 36 days with the average trade being worth of $987,207. The most recent stock trade was executed by William J Jr Teuber on 18 June 2021, trading 9,165 units of INOV stock currently worth $266,793.
What does Innovator ETFs Trust's logo look like?
Complete history of Mr. Pulido stock trades at Innovator ETFs Trust and QuidelOrtho
Innovator ETFs Trust executives and stock owners
Innovator ETFs Trust executives and other stock owners filed with the SEC include:
-
Peter De Bock,
Chief Administrative Officer -
Jonathan Boldt,
Chief Financial Officer -
Jason Capitel,
Chief Operating Officer -
Robert Wychulis,
President -
Isaac Kohane,
Independent Director -
William Teuber,
Independent Director -
Lee Roberts,
Independent Director -
William Green,
Independent Director -
Denise Fletcher,
Independent Director -
Mark Pulido,
Non-Independent Director -
Dr. Keith R. Dunleavy,
Founder, Chairman & CEO -
Keith Dunleavy,
Chairman of the Board, Chief Executive Officer -
Andre Hoffmann,
Independent Director -
Dr. Paige C. Kilian M.D.,
Chief Medical Officer -
Ingrid E. Olsen,
Chief People Officer -
Kim E. Collins,
Sr. VP of Corp. Marketing & Communications -
Beverly Allen,
Gen. Counsel, Chief Compliance & Privacy Officer -
Hulus Alpay,
VP of Investor Relations -
Geoff Charron,
Chief Technology Officer -
June Duchesne,
Chief Legal Officer -
Shauna L Vernal,
Chief Legal Officer -
Joseph R Rostock,
Chief Technology Officer -
Daniel L Rizzo,
Chief Innovation Officer -
Thomas R Kloster,
Chief Financial Officer -
Christopher E Greiner,
Chief Product Officer & COO -
John Michael Burgin,
Chief Product Officer -
Eron Kelly,
President